stoxline Quote Chart Rank Option Currency Glossary
ASLAN Pharmaceuticals Limited (ASLN)
0.469  0.019 (4.22%)    05-24 16:00
Open: 0.45
High: 0.47
Volume: 123,282
Pre. Close: 0.45
Low: 0.45
Market Cap: 11(M)
Technical analysis
2024-05-24 4:51:14 PM
Short term     
Mid term     
Targets 6-month :  0.61 1-year :  0.71
Resists First :  0.52 Second :  0.61
Pivot price 0.43
Supports First :  0.39 Second :  0.32
MAs MA(5) :  0.46 MA(20) :  0.43
MA(100) :  0.56 MA(250) :  1.4
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  43.7 D(3) :  49.1
RSI RSI(14): 50.9
52-week High :  4.26 Low :  0.39
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ASLN ] has closed below upper band by 20.6%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.47 - 0.47 0.47 - 0.48
Low: 0.44 - 0.45 0.45 - 0.45
Close: 0.46 - 0.47 0.47 - 0.47
Company Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Headline News

Mon, 13 May 2024
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Growth in Short Interest - Defense World

Thu, 09 May 2024
ASLAN Pharmaceuticals Excels in Eblasakimab Trials - - TipRanks

Thu, 09 May 2024
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mon, 06 May 2024
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Singapore News

Mon, 22 Apr 2024
Aslan Pharmaceuticals' Eblasakimab Shows Promise - - TipRanks

Mon, 22 Apr 2024
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 23 (M)
Shares Float 488 (M)
Held by Insiders 0.1 (%)
Held by Institutions 15.3 (%)
Shares Short 250 (K)
Shares Short P.Month 291 (K)
Stock Financials
EPS -2.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.75
Profit Margin 0 %
Operating Margin -364.5 %
Return on Assets (ttm) -63.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.53
EBITDA (p.s.) -1.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -47 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value -0.63
Price to Sales 0.88
Price to Cash Flow -0.23
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android